Citations (31)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Laura Orsolini, Domenico De Berardis & Umberto Volpe. (2020) Up-to-date expert opinion on the safety of recently developed antipsychotics. Expert Opinion on Drug Safety 19:8, pages 981-998.
Read now
Read now
Michael Davidson. (2018) The debate regarding maintenance treatment with antipsychotic drugs in schizophrenia. Dialogues in Clinical Neuroscience 20:3, pages 215-221.
Read now
Read now
Ricardo P. Garay, Carlos A. Zarate$suffix/text()$suffix/text(), Thomas Charpeaud, Leslie Citrome, Christoph U. Correll, Ahcène Hameg & Pierre-Michel Llorca. (2017) Investigational drugs in recent clinical trials for treatment-resistant depression. Expert Review of Neurotherapeutics 17:6, pages 593-609.
Read now
Read now
Articles from other publishers (28)
Song Lin, Ping Li, Jinglei Qin, Qi Liu, Jinling Zhang, Nana Meng, Cuicui Jia, Kunjie Zhu, Dan Lv, Lei Sun, Tinghuizi Shang, Yan Lin, Weipan Niu & Tianyang Wang. (2023) Exploring the key factors of schizophrenia relapse by integrating LC-MS/1H NMR metabolomics and weighted correlation network analysis. Clinica Chimica Acta 541, pages 117252.
Crossref
Crossref
Jitendra Kumar Sinha, Punya Sachdeva, Faizan Ahmad, Jasmine Sarkar, Raafiah Izhar, Ayesha Rahman & Shampa Ghosh. 2023. Cognizance of Schizophrenia:: A Profound Insight into the Psyche. Cognizance of Schizophrenia:: A Profound Insight into the Psyche
149
179
.
Anna Castañé, Montserrat Cano, Luis Ruiz-Avila, Lluís Miquel-Rio, Pau Celada, Francesc Artigas & Maurizio S Riga. (2022) Dual 5-HT3 and 5-HT6 Receptor Antagonist FPPQ Normalizes Phencyclidine-Induced Disruption of Brain Oscillatory Activity in Rats. International Journal of Neuropsychopharmacology 25:5, pages 425-431.
Crossref
Crossref
Matthew P. Baier, Maha G. Salman & Hibah O. Awwad. 2022. Role of Micronutrients in Brain Health. Role of Micronutrients in Brain Health
183
213
.
Cynthia Kwan, Imane Frouni & Philippe Huot. 2022. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
4231
4269
.
David M. Taylor, Thomas R. E. Barnes & Allan H. Young. 2021. The Maudsley Prescribing Guidelines in Psychiatry. The Maudsley Prescribing Guidelines in Psychiatry
1
224
.
Paweł Zajdel, Katarzyna Grychowska, Szczepan Mogilski, Rafał Kurczab, Grzegorz Satała, Ryszard Bugno, Tomasz Kos, Joanna Gołębiowska, Natalia Malikowska-Racia, Agnieszka Nikiforuk, Séverine Chaumont-Dubel, Xavier Bantreil, Maciej Pawłowski, Jean Martinez, Gilles Subra, Frédéric Lamaty, Philippe Marin, Andrzej J. Bojarski & Piotr Popik. (2021)
Structure-Based Design and Optimization of FPPQ, a Dual-Acting 5-HT
3
and 5-HT
6
Receptor Antagonist with Antipsychotic and Procognitive Properties
. Journal of Medicinal Chemistry 64:18, pages 13279-13298.
Crossref
Crossref
Rita Kočárová, Jiří Horáček & Robin Carhart-Harris. (2021) Does Psychedelic Therapy Have a Transdiagnostic Action and Prophylactic Potential?. Frontiers in Psychiatry 12.
Crossref
Crossref
Ari Brouwer & Robin Lester Carhart-Harris. (2020) Pivotal mental states. Journal of Psychopharmacology 35:4, pages 319-352.
Crossref
Crossref
Roberto Colangeli, G. Campbell Teskey & Giuseppe Di Giovanni. 2021. 5-HT Interaction with Other Neurotransmitters: Experimental Evidence and Therapeutic Relevance - Part A. 5-HT Interaction with Other Neurotransmitters: Experimental Evidence and Therapeutic Relevance - Part A
83
134
.
Cynthia Kwan, Imane Frouni & Philippe Huot. 2020. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
1
39
.
I. V. Semennov, Y. S. Zagryazhskaya, A. S. Piatoikina, T. V. Zhilyaeva, E. A. Manakova A., A. S. Blagonravova, E. V. Verbitskaya & G. E. Mazo. (2020) Tetrahydrobiopterin deficiency in schizophrenia as a new target for personalized medicine. V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY:4, pages 65-72.
Crossref
Crossref
Joshua T. Kantrowitz. (2020) Targeting Serotonin 5-HT2A Receptors to Better Treat Schizophrenia: Rationale and Current Approaches. CNS Drugs 34:9, pages 947-959.
Crossref
Crossref
Tara C. Delorme, Lalit K. Srivastava & Nicolas Cermakian. (2020) Are Circadian Disturbances a Core Pathophysiological Component of Schizophrenia?. Journal of Biological Rhythms 35:4, pages 325-339.
Crossref
Crossref
Kevin Kyle & Jeff M. Bronstein. (2020) Treatment of psychosis in Parkinson's disease and dementia with Lewy Bodies: A review. Parkinsonism & Related Disorders 75, pages 55-62.
Crossref
Crossref
Przemysław Zaręba, Anna K. Drabczyk, Jolanta Jaśkowska & Grzegorz Satała. (2020) Chemical puzzles in the search for new, flexible derivatives of lurasidone as antipsychotic drugs. Bioorganic & Medicinal Chemistry 28:10, pages 115459.
Crossref
Crossref
Karin Hrovatin, Tanja Kunej & Vita Dolžan. (2019) Genetic variability of serotonin pathway associated with schizophrenia onset, progression, and treatment. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 183:2, pages 113-127.
Crossref
Crossref
David Vanda, Paweł Zajdel & Miroslav Soural. (2019) Imidazopyridine-based selective and multifunctional ligands of biological targets associated with psychiatric and neurodegenerative diseases. European Journal of Medicinal Chemistry 181, pages 111569.
Crossref
Crossref
Agnieszka Jankowska, Grzegorz Satała, Anna Partyka, Anna Wesołowska, Andrzej J. Bojarski, Maciej Pawłowski & Grażyna Chłoń-Rzepa. (2019) Discovery and Development of Non-Dopaminergic Agents for the Treatment of Schizophrenia: Overview of the Preclinical and Early Clinical Studies. Current Medicinal Chemistry 26:25, pages 4885-4913.
Crossref
Crossref
Irfan Khan, Mohd Adil Shareef & C. Ganesh Kumar. (2019) An overview on the synthetic and medicinal perspectives of indenopyrazoles. European Journal of Medicinal Chemistry 178, pages 1-12.
Crossref
Crossref
Maria Eugênia Costa Queiroz, Mônia Aparecida Lemos Pinto, Jonas Carneiro Cruz, Juliana Mayumi Ushirohira, Isabella Caroline da Silva Dias & Jaime E Cecilio Hallak. (2019) Schizophrenia: recent advances in LC–MS/MS methods to determine antipsychotic drugs in biological samples. Bioanalysis 11:3, pages 215-231.
Crossref
Crossref
Dominik Strzelecki, Małgorzata Urban-Kowalczyk & Adam Wysokiński. (2018) Serum levels of TNF-alpha in patients with chronic schizophrenia during treatment augmentation with sarcosine (results of the PULSAR study). Psychiatry Research 268, pages 447-453.
Crossref
Crossref
Albert Yang & Shih-Jen Tsai. (2017) New Targets for Schizophrenia Treatment beyond the Dopamine Hypothesis. International Journal of Molecular Sciences 18:8, pages 1689.
Crossref
Crossref
Davide MartinoFrancesca Morgante. (2017) Movement disorders and chronic psychosis. Neurology Clinical Practice 7:2, pages 163-169.
Crossref
Crossref
Raquel N. Taddei, Federica Spinnato & Peter Jenner. 2017. Parkinson's Disease. Parkinson's Disease
407
452
.
Harini Sarva & Claire Henchcliffe. (2016) Evidence for the use of pimavanserin in the treatment of Parkinson’s disease psychosis. Therapeutic Advances in Neurological Disorders 9:6, pages 462-473.
Crossref
Crossref
Xudong Cao, Yin Chen, Yifang Zhang, Yinli Qiu, Minquan Yu, Xiangqing Xu, Xin Liu, Bi-Feng Liu & Guisen Zhang. (2016) Synthesis and biological evaluation of new 6-hydroxypyridazinone benzisoxazoles: Potential multi-receptor-targeting atypical antipsychotics. European Journal of Medicinal Chemistry 124, pages 713-728.
Crossref
Crossref
Nevena Divac, Radan Stojanović, Katarina Savić Vujović, Branislava Medić, Aleksandar Damjanović & Milica Prostran. (2016) The Efficacy and Safety of Antipsychotic Medications in the Treatment of Psychosis in Patients with Parkinson’s Disease. Behavioural Neurology 2016, pages 1-6.
Crossref
Crossref